SARS-CoV-2 – Asian Pacific Journal of Allergy and Immunology

March 21, 2025

Impact of pre-existing immunity on humoraland cellular responses to CoronaVac in SARS-CoV-2 variants: A focus on common human Coronaviruses

The global COVID-19 pandemic, caused by SARS-CoV-2, has highlighted the importance of understanding immune responses elicited by vaccines.

antibody and vaccination, HCoV, pre-existing immunity, SARS-CoV-2, T cell, variant

November 28, 2024

Chimeric peptides targeting the receptor-binding domainof SARS-CoV-2 variants inhibit ACE2 interaction

The receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein is pivotal in facilitating viral entry and serves as a major target for vaccine development and therapeutics. Despite undergoing mutations aimed at evading host immunity, certain regions within the RBD remain conserved.

angiotensin-converting enzyme 2 (ACE2), peptides, phage display, receptor-binding domain (RBD), respiratory disease, SARS-CoV-2

May 20, 2024

Host factors influencing variable symptoms of COVID-19

Similar to many other viruses, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) causes various symptoms in individuals who have been exposed to the virus. Individuals exposed to the virus can be asymptomatic, mild, severe, and critical for mortality.

cellular variants, emergent viruses, MHC polymorphism, SARS-CoV-2, uncertain symptoms, viral immunology, viral receptor

January 14, 2024

Responses of primary human nasal epithelial cellsto COVID-19 vaccine candidate

Upper respiratory tract is the primary target of SARS-CoV-2. Therefore, nasal immune responses act as the first line of defense against SARS-CoV-2 infection.

COVID-19 vaccine, delivery systems, primary human nasal epithelial cells, RBD, SARS-CoV-2

October 25, 2023

Global COVID-19 vaccination in infants and children:Effectiveness, safety, and challenges

COVID-19 Vaccines, which include mRNA and inactivated vaccines, have been proven effective and safe for infants and children aged more than six months in reducing the severity of the disease, hospitalization, multisystem inflammatory syndrome in children, and death.

Children, COVID-19 vaccines, infants, SARS-CoV-2

October 4, 2021

Innate immunity in COVID-19: Drivers of pathogenesis and potential therapeutic targets

A novel severe acute respiratory syndrome COVID-19 caused by coronavirus SARS-CoV-2 has been confirmed to infect more than 100 million people globally, with mortality reaching nearly 3 million as of March 2021.

COVID-19, hyperimmune activation, immunopathology, Innate immunity, SARS-CoV-2

December 29, 2020

Social restriction versus herd immunity policies in the early phase of the SARS-CoV-2 pandemic: A mathematical modelling study

Two main strategies to cope with the coronavirus disease 2019 (COVID-19) pandemic—lockdown (social restriction) and non-lockdown (herd immunity plan)—have been implemented in several countries.

control strategy, COVID-19, lockdown, mortality rate, SARS-CoV-2